Achillion Pharmaceuticals

Achillion Pharmaceuticals is a science-driven, patient-focused company seeking to leverage its strengths across the continuum from drug discovery to commercialization in its goal of providing better treatments for people with serious diseases. The Company employs a highly-disciplined discovery and development approach that has allowed it to pursue best-in-class therapy for chronic hepatitis C (HCV) and build a platform of potent and specific complement factor D inhibitors. Achillion is rapidly advancing its efforts to become a fully-integrated pharmaceutical company with a goal of bringing life-saving medicines to patients with rare diseases.
Company Growth (employees)
Type
Public
HQ
New Haven, US
Founded
1998
Size (employees)
81 (est)
Achillion Pharmaceuticals was founded in 1998 and is headquartered in New Haven, US

Achillion Pharmaceuticals Office Locations

Achillion Pharmaceuticals has an office in New Haven
New Haven, US (HQ)
300 George St

Achillion Pharmaceuticals Financials and Metrics

Achillion Pharmaceuticals Financials

Achillion Pharmaceuticals's revenue was reported to be $15 m in FY, 2016
USD

Net income (Q3, 2017)

(19.3 m)

EBIT (Q3, 2017)

(20.5 m)

Market capitalization (13-Nov-2017)

528.9 m

Cash (30-Sep-2017)

52.1 m

EV

477.2 m
Achillion Pharmaceuticals's current market capitalization is $528.9 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

66.1 m15 m

Revenue growth, %

(77%)

R&D expense

46.7 m53.5 m

General and administrative expense

12.7 m15.9 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Revenue

711 k711 k33.8 m

R&D expense

19.8 m13.3 m14.2 m16.7 m15.5 m18.3 m15.6 m

General and administrative expense

10.1 m5.4 m5.2 m4.8 m5.6 m5.4 m4.8 m

Operating expense total

29.9 m18.7 m19.3 m21.5 m21.1 m23.6 m20.5 m
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

33.5 m73.7 m81.7 m77.3 m

Accounts Receivable

223.2 m

Inventories

2.5 m1.9 m2.7 m3.5 m

Current Assets

124.8 m154.9 m462.6 m382.5 m
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Cash

25.6 m34.1 m33.3 m39.6 m46.7 m61.7 m150.4 m58.7 m33.8 m40.4 m43.1 m35.4 m52.1 m

Current Assets

141.9 m142.6 m133.6 m128.7 m255.6 m249.5 m465.3 m443 m429.1 m411.8 m383.4 m355.2 m327 m

Total Assets

176.1 m148 m135.2 m130.6 m279.4 m266.1 m479.5 m448.7 m432.4 m415.2 m393.4 m376.9 m360.4 m

Accounts Payable

4.8 m3.6 m2 m2.6 m8 m11.5 m4.9 m6.6 m5.8 m5.4 m4.1 m3 m8.1 m
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(58.9 m)(69 m)(5 m)(61.7 m)

Depreciation and Amortization

399 k489 k694 k955 k

Inventories

(104 k)575 k(837 k)(721 k)

Accounts Payable

315 k1.8 m(2.3 m)2.7 m
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Net Income

(45.6 m)(16.1 m)(31.7 m)(47.4 m)(19.3 m)(48.2 m)(22 m)(18.1 m)(36.5 m)(57.3 m)(20.2 m)(42.7 m)(62 m)

Depreciation and Amortization

296 k111 k232 k353 k160 k321 k505 k192 k432 k690 k295 k565 k842 k

Accounts Payable

569 k(950 k)(2.6 m)(2 m)1.5 m5 m(1.5 m)2.4 m1.3 m1.1 m(2.7 m)(3.9 m)1.3 m

Cash From Operating Activities

(39.7 m)(13.4 m)(27.2 m)(39.3 m)(17.3 m)(34.2 m)21.2 m(16.2 m)(33.1 m)(48.5 m)(5.8 m)(22.7 m)
Y, 2017

EV/EBIT

-23.3 x

Financial Leverage

1 x
Show all financial metrics

Achillion Pharmaceuticals Market Value History

Achillion Pharmaceuticals's Web-traffic and Trends

Achillion Pharmaceuticals Online and Social Media Presence

Achillion Pharmaceuticals Company Life and Culture

You may also be interested in